Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 22 MAY 2025

Regeneron Awarded $407 Million In Amgen Antitrust Suit

Goodwin Procter LLP
Explore more from Goodwin Procter LLP

On May 15, 2025, a jury returned a verdict finding Amgen Inc. ("Amgen") liable for antitrust violations and awarding Regeneron Pharmaceuticals, Inc. ("Regeneron") over $400 million in damages.

United StatesAntitrust/Competition Law
Darlene Staines
Darlene Staines

On May 15, 2025, a jury returned a verdict finding Amgen Inc. ("Amgen") liable for antitrust violations and awarding Regeneron Pharmaceuticals, Inc. ("Regeneron") over $400 million in damages.

As we reported previously, Regeneron filed its antitrust lawsuit in 2022 in the U.S. District Court for the District of Delaware, alleging Amgen was engaged in an "unlawful, anticompetitive bundling scheme" by offering rebates on Otezla® and Enbrel® when purchased with Repatha®, forcing Third-Party Payors to "jettison Regeneron's Praluent® in favor of Amgen's Repatha®." Regeneron also alleged Amgen was pricing Repatha® below cost, making it impossible for Regeneron to compete without losing money on Praluent®. Amgen's motion to dismiss was denied in 2023.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Right To Repair Alert: Deere & Company Reaches Settlement With FTC, States

The Federal Trade Commission and five State Attorneys General have reached a landmark settlement with Deere & Company in a year-and-a-half antitrust litigation over the agricultural equipment manufacturer's restrictions on repair resources. The stipulated order, if approved, will require Deere to provide farmers and independent repair providers with the same repair tools and technical resources available to authorized dealers for a period of ten years.
United StatesAntitrust/Competition Law
Axinn LLP
Axinn LLP
Article

New York-Presbyterian Hospital Ruling Signals Widening Antitrust Exposure For Hospital Contracting Practices

A federal court ruling against New York Presbyterian Hospital validates DOJ theories that market power can be proven through supracompetitive pricing rather than market share alone, and that exclusionary conduct is not required for antitrust claims. This decision expands potential antitrust exposure for hospital systems employing restrictive contracting practices like all-products provisions, anti-tiering terms, and gag clauses...
United StatesAntitrust/Competition Law
Crowell & Moring LLP
Crowell & Moring LLP
Article

Life Sciences Antitrust Quarterly Update Q3 2026

This quarterly update examines key antitrust developments in life sciences during Q3 2026, including the FTC's investigation of Boston Scientific's $14.5 billion Penumbra acquisition, the DOJ's record $250 million HSR penalty against KKR, and European regulatory actions involving Sanofi and Align Technology. The analysis also explores the UK's pro-innovation approach to healthcare AI regulation and its implications for the medical device industry.
GlobalAntitrust/Competition Law
Goodwin Procter LLP
Goodwin Procter LLP